Back to top

AstraZeneca’s Saphnelo Shows Promising Results in Phase III Lupus Trial

An announcement from AstraZeneca ( ($GB:AZN) ) is now available. AstraZeneca announced positive interim results from the Phase III TULIP-SC trial, ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AstraZeneca PLC (AZN)